Circulating Glypican-4 Is a Predictor of 24-Month Overall Survival in Metastatic Breast Cancer
Sign Up to like & getrecommendations! Published in 2023 at "Oncology Research and Treatment"
DOI: 10.1159/000529547
Abstract: Introduction: Endocrine treatment combined with CDK4/6 inhibitors is the preferred treatment strategy in patients presenting with ER-positive/HER2-negative breast cancer, but the clinical course remains highly variable among individual patients. There is an unmet need for… read more here.
Keywords: circulating glypican; breast cancer; gpc4; metastatic breast ... See more keywords